Aarey Drugs & Pharmaceuticals Ltd.
Snapshot View

39.85 +0.15 ▲0.4%

20 May 2022, 04:01:00 PM
Volume: 9,787

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.aareydrugs.com
Market Cap 101.54 Cr.
Enterprise Value(EV) 123.67 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 3.43 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 11.66 Trailing Twelve Months Ending 2021-12
Industry PE 29.26 Trailing Twelve Months Ending 2021-12
Book Value / Share 45.06 Trailing Twelve Months Ending 2021-12
Price to Book Value 0.89 Calculated using Price: 40.00
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 2.54 Cr. 25,384,684 Shares
FaceValue 10
Company Profile

Aarey Drugs & Pharmaceuticals Ltd. was established in 1990. The company is engaged in the manufacturing of drugs and intermediates such as metronidazole, metronidazole benzoate, methyl, and nitro imidazole. The company is based in Thane, India.

The  company also export its products to various other countries like Germany, Sri Lanka, Pakistan, Nepal and a number of African countries and is looking to establish its trade relations in other parts of the world as well.

Product range of the company includes: API/Intermediate

  • Metronidazol
  • Metronidazole Benzoate
  • 2 Methyl -5-Nitro Imidazole

Drug deliveryPharmaceuticals / Therapeutics

Therapeutic targets of the company's products are:

  • Allergy
  • Dermatology
  • Infectious Diseases

Recent development

Aarey Drugs & Pharmaceuticals  has recently informed that  Atul A Zatakia has resigned from the Company as a Director with effect from March 01, 2009.  

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.38%
1 Week
+6.27%
1 Month
-12.61%
3 Month
-9.33%
6 Month
+12.89%
1 Year
+26.91%
2 Year
+121.39%
5 Year
-64.94%
10 Year
+88.59%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 1.99 3.10 3.12 3.58 12.90 9.80 8.07 6.65 6.98
Return on Capital Employed (%) 4.42 5.83 6.69 7.23 22.21 14.14 12.05 8.48 9.46
Return on Assets (%) 0.68 0.98 0.98 1.07 4.09 3.96 4.15 3.41 3.05

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 33 35 35 37 49 80 87 92 99 104
Non Curr. Liab. 0 0 0 2 1 2 1 2 2
Curr. Liab. 73 72 80 88 92 88 58 100 133 158
Minority Int.
Equity & Liab. 107 107 115 125 143 170 146 194 233 264
Non Curr. Assets 8 5 6 8 13 13 13 13 15 19
Curr. Assets 99 102 109 117 130 157 133 181 218 245
Misc. Exp. not W/O 0 0 0
Total Assets 107 107 115 125 143 170 146 194 233 264

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 172 200 213 246 396 349 355 300 348 551
Other Income 0 2 3 3 3 3 4 7 7 3
Total Income 173 201 216 249 399 352 359 307 355 554
Total Expenditure -170 -198 -212 -245 -386 -341 -347 -297 -344 -539
PBIDT 2 3 4 4 13 11 12 10 12 15
Interest -1 -1 -1 -2 -4 -2 -2 -2 -2 -2
Depreciation -1 -1 -1 -1 -1 -1 -1 -1 -1 -2
Taxation 0 0 0 -1 -3 -2 -2 -1 -2 -3
Exceptional Items
PAT 1 1 1 1 5 6 7 6 7 9
Adjusted EPS 0 1 1 1 3 3 3 2 3 4

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. -9 3 0 3 6 1 -20 1 3 5
Cash Fr. Inv. 0 -3 2 -2 -3 -5 -1 -1 -1 -3
Cash Fr. Finan. 10 -1 -1 -2 -2 4 23 -2 -2 -2
Net Change 1 -1 0 -1 1 -1 2 -3 0 0
Cash & Cash Eqvt 1 1 1 0 2 1 3 0 1 1

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 49.38 49.38 49.38 49.38 49.38 49.38 49.38 48.05 48.06
Public 50.62 50.62 50.62 50.62 50.62 50.62 50.62 51.95 51.94
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 29 Apr 2022
Statement Of Deviation(S) Or Variation (S) Under Regulation 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Statement of deviation(s) or variation (s) under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
Tue, 19 Apr 2022
Compliance Certificate Of Regulation 7(3) Of SEBI (Listing Obligations And Disclosures Requirements) Regulations 2015
Compliance Certificate of Regulation 7(3) of SEBI ((Listing Obligations and Disclosures Requirements) Regulations 2015
Wed, 13 Apr 2022
Certificate Under Regulation 40(9) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.
Certificate under Regulation 40(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015.

Technical Scans View Details

Fri, 20 May 2022
Opening at High Opening at High
High Decrease 1 Month High Decrease 1 Month
High Increase 2 Years High Increase 2 Years
Black Marubozu Black Marubozu
Thu, 19 May 2022
Opening at High Opening at High

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%